Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

J.P. Morgan Keeps 'Overweight' on Gilead Sciences


J.P. Morgan reiterates overweight on Gilead Sciences (GILD).

Analyst David Molowa says he believes Gilead's FTC drug will receive approval by its July 3 FDA action date. He says his confidence has increased, given the FDA's recent positive actions on several other biotech products, and FTC's safety and efficacy in treating HIV. He expects further outperformance to be driven by superior operating performance.

Molowa raised the 92 cents 2003 earnings per share estimates to 97 cents and upped the $1.58 2004 estimate to $1.78 -- this is well ahead of consensus estimates. He says Gilead is an attractive investment vs. its biopharmaceutical peers.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus